| Mar 21 2024 |
Legalizing LSD? FDA Says Mm-hmm to MM120 |
Bradley Arant Boult Cummings LLP |
| Mar 20 2024 |
Medicare Changes to Make Drug Coverage More Manageable in 2025 |
Polsinelli PC |
| Mar 20 2024 |
2024 Litigation Look Ahead Series: Key Cases That Could Impact CERCLA Liability and Contribution Claims |
Beveridge & Diamond PC |
| Mar 20 2024 |
FDA Issues Import Alert for Food Products Containing Chemical Contaminants including PFAS |
Keller and Heckman LLP |
| Mar 20 2024 |
Canada Grants its First Approval for Animal-Free Milk Protein |
Keller and Heckman LLP |
| Mar 20 2024 |
Synchronizing with Cyborgs: Who Am I – Human or Machine? |
Nishith Desai Associates |
| Mar 20 2024 |
FDA Releases Draft Guidance on New Dietary Ingredient Notification Procedures, Timelines |
Epstein Becker & Green, P.C. |
| Mar 19 2024 |
Behavioral Health M&A 2024 Legal Trends |
Polsinelli PC |
| Mar 19 2024 |
TTB Ramps Up Tax Audits and Enforcement |
McDermott Will & Schulte LLP |
| Mar 19 2024 |
Time to Refresh? FDA Issues Draft Guidance on Key Information and Informed Consent |
Sheppard, Mullin, Richter & Hampton LLP |
| Mar 19 2024 |
GT Legal Food Talk Episode 24: Tracking Top Food & Beverage Trends in 2024 [Podcast] |
Greenberg Traurig, LLP |
| Mar 19 2024 |
Veep Urges DEA to Reschedule Marijuana “As Quickly as Possible” |
Bradley Arant Boult Cummings LLP |
| Mar 19 2024 |
Food Industry Group Files Brief in Support of GMO Labeling Rule |
Keller and Heckman LLP |
| Mar 19 2024 |
FDA and OHRP Issue Joint Draft Guidance on Content, Organization, and Presentation of Consent Forms for Research Participants |
Epstein Becker & Green, P.C. |
| Mar 18 2024 |
Cadwalader Climate (March 18, 2024) |
Cadwalader, Wickersham & Taft LLP |
| Mar 18 2024 |
China Announces the Standard for Food Packaging Adhesives |
Keller and Heckman LLP |
| Mar 18 2024 |
Nevada Supreme Court Reverses $48 Million Verdict, Concludes Hospitals Do Not Owe Fiduciary Duty to Patients in the Provision of Medical Services |
Wilson Elser Moskowitz Edelman & Dicker LLP |
| Mar 15 2024 |
Recent Federal Developments for March 2024 |
Bergeson & Campbell, P.C. |
| Mar 15 2024 |
China Announces the Standard for Food-Contact Adhesives |
Keller and Heckman LLP |
| Mar 15 2024 |
USDA FSIS Final Rule for Voluntary “Product of the USA” Claims |
Keller and Heckman LLP |
| Mar 14 2024 |
Clinical Research: FDA Issues Draft Guidance on Informed Consent |
Foley & Lardner LLP |
| Mar 14 2024 |
Optimizing Obviousness: Routine Optimization Can Fill in Prior Art Gaps |
McDermott Will & Schulte LLP |
| Mar 14 2024 |
My Healthy Food Product is Ready to Go to Market – What About its Packaging? |
Foley & Lardner LLP |
| Mar 14 2024 |
Draft European Commission Proposal May Significantly Impact Plastic Food-Contact Materials |
Keller and Heckman LLP |
| Mar 13 2024 |
White House OSTP Posts Readout of NNI Symposium Celebrating 20th Anniversary of the 21st Century Nanotechnology R&D Act |
Bergeson & Campbell, P.C. |
| Mar 13 2024 |
Clinical Trials: FDA Issues Finalized Charging Guidance for Investigational Drug Use |
Foley & Lardner LLP |
| Mar 13 2024 |
Oregon Reinstates $20 Million Subrogation Case |
Wilson Elser Moskowitz Edelman & Dicker LLP |
| Mar 13 2024 |
Adverse Reports Related to Certain Tejocote Root Dietary Supplements Continue |
Keller and Heckman LLP |
| Mar 13 2024 |
FDA Issues Guidance for Foods Made from Genome-Edited Plants |
Womble Bond Dickinson (US) LLP |
| Mar 13 2024 |
Litigation Minute: Beauty from Within and the Confusing Claims Landscape |
K&L Gates LLP |
| Mar 13 2024 |
This Week in 340B: March 5 – 12, 2024 |
McDermott Will & Schulte LLP |
| Mar 12 2024 |
FDA Needs a New Approach to AI/ML-Enabled Medical Devices |
Mintz |
| Mar 12 2024 |
Cancer Drugs: Antibody Drug Conjugates (ADCs) Keep Growing |
Foley & Lardner LLP |
| Mar 12 2024 |
FDA Publishes Stance on Titanium Dioxide in Food |
Keller and Heckman LLP |
| Mar 11 2024 |
NIOSH Highlights 20 Years of Research on Engineering Controls for Nanotechnology |
Bergeson & Campbell, P.C. |
